
More patients to become eligible for chronic kidney disease treatment
The UK National Institute for Health and Care Excellence (NICE) has published updated Final Draft Guidance recommending AstraZeneca’s Forxiga (dapagliflozin) as an option to treat chronic kidney disease (CKD) in adults in certain cases. This is the case if: It is an add-on to optimised standard care including the highest… Read More















